title: Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.
abstract: To clarify the clinical impact of prior use of azacitidine (AZA) on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS), we retrospectively reviewed the clinical outcomes of 15 MDS patients who were treated with AZA before allo-HSCT (AZA group). We compared the outcomes of these 15 patients with 52 MDS patients who were solely given the best supportive care (BSC) before allo-HSCT (BSC group). Although patients in the AZA group were older with higher International Prognostic Scoring System (IPSS) scores compared to patients in the BSC group, no significant differences were found between the two groups in overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR) or non-relapse mortality. However, in patients with a higher IPSS score (Int-2/High), pre-transplant AZA may provide better OS and DFS and lower CIR. Acute graft-versus-host disease rates were similar between the two groups. These results should be reassuring to patients with high-risk MDS receiving AZA before allo-HSCT.
authors.affiliation: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan, gaku.oshikawa@gmail.com.
authors.forename: Gaku
authors.initials: G
authors.lastname: Oshikawa
authors.forename: Kousuke
authors.initials: K
authors.lastname: Yoshioka
authors.forename: Yukie
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Naoki
authors.initials: N
authors.lastname: Shingai
authors.forename: Shuntaro
authors.initials: S
authors.lastname: Ikegawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kobayashil
authors.forename: Noriko
authors.initials: N
authors.lastname: Doki
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Kakihana
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Ohashi
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001374:Azacitidine / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000601:surgery* / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods; D055815:Young Adult
chemical_list: D004791:Enzyme Inhibitors; D001374:Azacitidine
references.citation: Clin Adv Hematol Oncol. 2010 Jan;8(1):40-6
references.pmid: 20351682
references.citation: Blood. 2006 Jul 15;108(2):419-25
references.pmid: 16609072
references.citation: J Clin Oncol. 2002 May 15;20(10):2429-40
references.pmid: 12011120
references.citation: Br J Haematol. 1976 Aug;33(4):451-8
references.pmid: 188440
references.citation: Lancet Oncol. 2009 Mar;10(3):223-32
references.pmid: 19230772
references.citation: Bone Marrow Transplant. 2010 Feb;45(2):255-60
references.pmid: 19543327
references.citation: Eur J Haematol. 2013 Feb;90(2):111-20
references.pmid: 23113470
references.citation: Blood. 2010 Jan 7;115(1):107-21
references.pmid: 19887673
references.citation: J Clin Oncol. 2012 Dec 20;30(36):4533-40
references.pmid: 23109707
references.citation: Bone Marrow Transplant. 2012 Mar;47(3):374-9
references.pmid: 21478916
references.citation: Hematology Am Soc Hematol Educ Program. 2005;:384-9
references.pmid: 16304408
references.citation: Blood. 2010 Jul 8;116(1):129-39
references.pmid: 20424188
references.citation: Bone Marrow Transplant. 2013 Mar;48(3):452-8
references.pmid: 23208313
references.citation: Biol Blood Marrow Transplant. 2012 Aug;18(8):1211-8
references.pmid: 22252125
references.citation: Blood. 1997 Mar 15;89(6):2079-88
references.pmid: 9058730
references.citation: Blood Rev. 2012 Nov;26(6):247-54
references.pmid: 22981712